Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on patients with a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically when this cancer has a certain genetic marker called ALK-positive. The stages of cancer involved range from Stage Ib, with tumors at least 4 centimeters, to Stage IIIa. This trial looks at how well two different treatments work after the cancer has been surgically removed: a drug named Alectinib and a group of drugs known as platinum-based chemotherapy.

Alectinib is provided in capsule form and taken orally. It belongs to a group of drugs that target specific cancer cells with the ALK marker, aiming to stop their growth and spread. Platinum-based chemotherapy involves medications like Carboplatin, Cisplatin, and Pemetrexed, which are given through an infusion, meaning they are administered directly into the bloodstream. This form of chemotherapy uses drugs that contain the metal platinum, which helps to damage the DNA of cancer cells, preventing them from dividing and growing.

The purpose of this study is to compare how effectively these treatments prevent cancer from returning in patients who have already had their tumors removed. By looking at which treatment helps patients remain cancer-free for a longer period, the study aims to determine the better option for use after surgery in this specific type of lung cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment

    Upon joining the study, confirmation of complete removal of the lung cancer is required. The cancer must be at Stage Ib (tumors 4 cm or larger) to Stage IIIa and must be positive for a specific protein called anaplastic lymphoma kinase (ALK).

    Eligibility includes having a good performance status, adequate blood and kidney function, and the ability to follow the study schedule.

  2. Step 2

    Randomization

    Participants are randomly assigned to one of two groups: one receiving alectinib and the other receiving platinum-based chemotherapy.

  3. Step 3

    Treatment with alectinib

    If assigned to the alectinib group, take 150 mg hard capsules orally. The frequency and duration of administration will be specified by the study protocol.

  4. Step 4

    Treatment with platinum-based chemotherapy

    If assigned to the chemotherapy group, receive one of the following medications through intravenous infusion: carboplatin, cisplatin, pemetrexed, gemcitabine hydrochloride, or vinorelbine. The specific medication, dosage, and schedule will be determined by the study protocol.

  5. Step 5

    Monitoring and assessments

    Regular visits are required to monitor health status, including assessments of disease-free survival, overall survival, and any side effects.

    Blood tests and other laboratory evaluations will be conducted to check for any abnormal findings.

    Vital signs and heart function will be monitored through electrocardiograms.

  6. Step 6

    Completion

    The study is expected to conclude by November 19, 2026. Final assessments will be conducted to evaluate the outcomes of the treatment.

Who can join the trial?

7 criteria

  • The patient must have had a complete removal of a lung tumor that was confirmed by a lab test to be Stage Ib (tumor size 4 cm or larger) to Stage IIIa, with no cancer cells left at the edges of the removed tissue. This surgery should have been done 4 to 12 weeks before joining the study.
  • The patient must have a documented ALK-positive disease, which means their cancer has a specific genetic change, confirmed by a test approved by health authorities.
  • The patient must be able to receive a platinum-based chemotherapy treatment, which is a type of cancer treatment, according to local medical guidelines.
  • The patient must have an Eastern Cooperative Oncology Group Performance Status of Grade 0 or 1, which means they are fully active or have some symptoms but can still carry out light work.
  • The patient must have adequate blood and kidney function, meaning their blood and kidneys are working well enough to participate in the study.
  • The patient must be willing and able to attend scheduled visits, follow treatment plans, and undergo lab tests and other study procedures.
  • The study is open to both male and female participants.

Who cannot join the trial?

10 criteria

  • Patients who have not had their lung cancer completely removed by surgery.
  • Patients with lung cancer that is not classified as Stage Ib (tumors 4 cm or larger) to Stage IIIa.
  • Patients whose lung cancer is not positive for Anaplastic Lymphoma Kinase (ALK). ALK is a specific gene that can be involved in the growth of cancer cells.
  • Patients who have not been diagnosed with Non-Small Cell Lung Cancer (NSCLC). NSCLC is a type of lung cancer that grows and spreads more slowly than small cell lung cancer.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to follow the study procedures or attend the required visits.
  • Patients who have other medical conditions that might interfere with the study or its results.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have had certain treatments for cancer recently, which might affect the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Alectinib

    is a medication used in this trial to treat patients with a specific type of lung cancer known as ALK-positive non-small-cell lung cancer. It works by targeting and blocking the activity of a protein that helps cancer cells grow, which may help to stop or slow down the growth of the cancer.

  • Platinum-Based Chemotherapy

    is a standard treatment for various types of cancer, including lung cancer. It involves using drugs that contain the metal platinum to damage the DNA of cancer cells, which can prevent them from dividing and growing. This type of chemotherapy is often used after surgery to help eliminate any remaining cancer cells.

What is already known about the treatment

Alectinib – Alectinib is administered orally in the form of capsules. It is currently being studied in clinical trials as a treatment for patients with completely resected, Stage Ib to Stage IIIa Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC). The main therapeutic indication for alectinib is to improve disease-free survival in these patients. At the molecular level, alectinib works by inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells. It is classified as a tyrosine kinase inhibitor, specifically targeting the ALK protein.

Investigated diseases

Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is characterized by the uncontrolled growth of cells in the lung tissues, which can form tumors. In the case of ALK-positive NSCLC, a genetic mutation in the anaplastic lymphoma kinase (ALK) gene leads to cancer development. The disease progresses through stages, with Stage Ib indicating tumors that are 4 cm or larger, and Stage IIIa involving more extensive spread within the lung or to nearby lymph nodes. The progression of NSCLC can vary, with some tumors growing slowly and others more rapidly.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506861-76-00Protocol codeBO40336Estimated enrolment257 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.